logo

Last Update

This profile was last updated on 7/20/2014 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Ronald Hendrickson?

Ronald C. Hendrickson

Head

Microchemistry Core Facility

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Background Information

Employment History

Director

MDS Proteomics Inc


Director of Proteomics At Research Laboratories

Merck & Co. , Inc.


Head of Business Development. Www.Protana.Com

Protana Inc.


Affiliations

MSKCC

Laboratory Member and Head of Proteomics and Microchemistry Core Facility


Rosetta Biosoftware

Scientific Advisory Board Member


Education

B.S.

Chemistry

University of Washington


Ph.D.

Chemistry

University of Virginia


Web References(32 Total References)


www.mskcc.org

In addition, Ronald Hendrickson, Head of Memorial Sloan Kettering's Proteomics and Microchemistry Core Facility, used a highly sophisticated version of a technique called mass spectrometry, which separates the parts of a molecule based on their masses, to verify that the structure created by the Memorial Sloan Kettering team was the same as the natural glycoprotein.
Ronald C. Hendrickson


www.keystonesymposia.org [cached]

* Ronald Hendrickson, Memorial Sloan Kettering Cancer Center, USA


www.milestonedevelopment.com [cached]

Ronald Hendrickson, Merck Research Laboratories


www.rosettabio.com [cached]

Dr. Ronald C. Hendrickson, is the director of Proteomics in the department of Molecular Profiling at Merck Research Laboratories in Rahway, New Jersey, USA.
Currently, he is applying state-of-the-art mass spectrometry techniques to rapidly identify and quantify changes in proteins related to disease or therapeutic agents. Prior to joining Merck, Dr. Hendrickson served as a Vice President for MDS Proteomics (Protana), a leading proteomics company founded on emerging informatics tools and nano-electrospray technology developed the EMBL. He also served as Chairman of the MDS Proteomics-Harvard Partners Joint Steering Committee. This strategic alliance was established to combine the collective expertise of clinical investigators and state of the art proteomics to speed the discovery, development and commercialization of innovative healthcare products. Dr. Hendrickson joined Protana in Odense Denmark to work with Matthias Mann and Ole Vorm At Protana, his research efforts expanded into large-scale protein-protein interaction studies using yeast as a model organism. Prior to joining Protana, Dr. Hendrickson was employed by Corixa Corporation in Seattle, Washington, USA. His research at Corixa involved identifying tumor antigens and serological markers for Breast cancer and Tuberculosis. Dr. Hendrickson received his B.S. in Chemistry from the University of Washington and his Ph.D. in Chemistry from the University of Virginia. Under the guidance of Professor Donald F. Hunt, Dr. Hendrickson developed and applied high-sensitivity mass spectrometry to biological research.


www.rosettainpharmatics.com [cached]

Dr. Ronald C. Hendrickson, is the director of Proteomics in the department of Molecular Profiling at Merck Research Laboratories in Rahway, New Jersey, USA.Currently, he is applying state-of-the-art mass spectrometry techniques to rapidly identify and quantify changes in proteins related to disease or therapeutic agents.Prior to joining Merck, Dr. Hendrickson served as a Vice President for MDS Proteomics (Protana), a leading proteomics company founded on emerging informatics tools and nano-electrospray technology developed the EMBL.He also served as Chairman of the MDS Proteomics-Harvard Partners Joint Steering Committee.This strategic alliance was established to combine the collective expertise of clinical investigators and state of the art proteomics to speed the discovery, development and commercialization of innovative healthcare products. Dr. Hendrickson joined Protana in Odense Denmark to work with Matthias Mann and Ole Vorm At Protana, his research efforts expanded into large-scale protein-protein interaction studies using yeast as a model organism.Prior to joining Protana, Dr. Hendrickson was employed by Corixa Corporation in Seattle, Washington, USA.His research at Corixa involved identifying tumor antigens and serological markers for Breast cancer and Tuberculosis.Dr. Hendrickson received his B.S. in Chemistry from the University of Washington and his Ph.D. in Chemistry from the University of Virginia.Under the guidance of Professor Donald F. Hunt, Dr. Hendrickson developed and applied high-sensitivity mass spectrometry to biological research.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory